|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's Range||6.75 - 7.11|
|52 Week Range||6.25 - 96.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||118.75|
While small-cap stocks, such as InVivo Therapeutics Holdings Corp (NASDAQ:NVIV) with its market cap of US$11.35M, are popular for their explosive growth, investors should also be aware of their balanceRead More...
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $3.34. InVivo shares have decreased 57 percent since the beginning of the year. In the final minutes of trading on ...
InVivo Therapeutics Holdings Corp. today provided a business and clinical update and reported financial results for the quarter ended March 31, 2018.
Shares of InVivo also headed higher after a reverse stock split this week. InVivo is also in the process of finalizing a lease assignment that the company expects will result in lease-related savings of approximately $3M through 2019.
InVivo Therapeutics Holdings Corp. today provided a general business update. The company is announcing a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock.
InVivo Therapeutics Holdings Corp. today announced top-line findings from its CONTEMPO Registry Study, designed to provide comprehensive natural history benchmarks for Neuro-Spinal Scaffold™ clinical study results.
The Cambridge, Massachusetts-based company said it had a loss of 13 cents per share. For the year, the company reported that its loss widened to $26.7 million, or 81 cents per share. The company's shares ...
InVivo Therapeutics Holdings Corp (NASDAQ:NVIV), a medical equipment company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. Less-covered,Read More...
NEW YORK, NY / ACCESSWIRE / March 9, 2018 / Shares of Johnson & Johnson saw a slight close in the green yesterday despite announcing that the average price paid for its medicines had dropped last year. ...
InVivo Therapeutics Holdings Corp. today announced that the company has received supplemental Investigational Device Exemption approval from the US Food and Drug Administration for a second pivotal clinical study of the company’s Neuro-Spinal Scaffold™ in patients with acute spinal cord injury .
InVivo Therapeutics Holdings Corp. today announced that Richard Toselli, M.D., has been appointed President and Chief Executive Officer of InVivo, having been appointed the company’s Acting CEO in December 2017.
LONDON, UK / ACCESSWIRE / January 29, 2018 / Active-Investors.com has just released a free research report on InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV ) ("InVivo Therapeutics"). If you ...
InVivo Therapeutics Holdings Corp. today announced that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC , a
InVivo Therapeutics Holdings Corp. today announced the latest results from The INSPIRE Study .
InVivo Therapeutics Holdings Corp. today announced that Richard Toselli, M.D., has been appointed Acting Chief Executive Officer of InVivo, replacing Mark D. Perrin, who has resigned as Chief Executive Officer and Chairman of InVivo’s Board of Directors.
The Cambridge, Massachusetts-based company said it had a loss of 28 cents per share. In the final minutes of trading on Monday, the company's shares hit $1.45. A year ago, they were trading at $4.40. _____ ...
InVivo Therapeutics Holdings Corp (NASDAQ:NVIV), a healthcare equipment and supplies company based in United States, saw a significant share price rise of over 20% in the past couple of monthsRead More...
InVivo Therapeutics Holdings Corp. today announced that Stuart Lee, M.D., Investigator at Vidant Medical Center in Greenville, North Carolina, will be giving an oral platform presentation titled “Histopathology of Necrotic Spinal Cord Tissue Exudate Collected During Surgical Implantation of a Biodegradable Scaffold Following Acute Spinal Cord Injury: Pre-clinical and Clinical Findings” at the 2017 ...
InVivo Therapeutics Holdings Corp. today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 12:00pm ET at the Sofitel New York Hotel, in Manhattan.
InVivo Therapeutics Holdings Corp. today announced the publication of an article titled “Relationship of American Spinal Injury Association Impairment Scale Grade to Post-injury Hospitalization and Costs in Thoracic Spinal Cord Injury” in the journal Neurosurgery.
InVivo Therapeutics Holdings Corp. today announced that it is executing a strategic restructuring in order to focus on The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury.
InVivo Therapeutics Holdings Corp. today announced that it had exchanged certain outstanding warrants that were issued as part of a financing in 2014 for shares of the company’s common stock.